The policy stagnation of recent years, where change has been almost entirely focused on pricing, belies a history of significant structural shifts to ensure the program can better accommodate patient needs. …
The system can innovate for patients, when it wants, but history shows it rarely involves HTA
May 31, 2023 Latest NewsBioPharmaComment
Latest Video
New Stories
-
Stakeholder backing for another PBS co-pay reduction
March 20, 2025 - - Latest News -
If our own government isn't going to do anything, then we can only hope for intervention
March 20, 2025 - - Latest News -
US price negotiation power reveals a very different approach to patient input
March 20, 2025 - - Latest News -
Brisbane-based drugmaker QBiotics celebrates 25 years since its creation
March 19, 2025 - - Australian Biotech -
Imugene's azer-cel granted FDA Fast Track Designation in blood cancer
March 19, 2025 - - Australian Biotech -
Island raises $2.72 million through exercise of listed options
March 19, 2025 - - Australian Biotech -
All manufacturers decide to participate in the second cycle of US price negotiation
March 19, 2025 - - Latest News